Article Text
Statistics from Altmetric.com
We read with interest the paper by Bajaj et al recently published on Gut, reporting high mortality rates in cirrhotic patients with COVID-19, as we previously showed in 50 cirrhotics enrolled in our study.1 2
Although both studies reported an increased risk of mortality following SARS-CoV-2 infection in cirrhotics, as recently confirmed by other studies in both cirrhotic and liver transplanted patients, they differ for some aspects.1–4 Bajaj and colleagues enrolled younger patients (61.0±10.6 vs 67.6±10.1 years old), mostly women (73% vs 30%), and they found similar survival in cirrhotic patients with and without COVID-19, in contrast with what we previously reported.1 2 In the North American cohort, the Charlson Comorbidity Index (CCI) was independently associated with mortality (OR 1.23, 95% CI 1.11 to 1.37, p<0.0001),1 while in our cohort CLIF-OF (OR 1.77, 95% CI 1.24 to 2.54, p=0.002) and moderate to severe lung failure (OR 1.86, 95% 1.00–3.44, p=0.048) independently predicted mortality according to a logistic regression model.5 In the …